7Baggers

Quanterix Corporation
(NASDAQ:QTRX) 

QTRX stock logo

Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitiv...

Founded: 2007
Full Time Employees: 248
Sector: Healthcare
Industry: Medical Devices
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 
                                    
      revenues:
    		                                
      product revenue
    		25,479,000 29,218,000 26,151,000 16,832,000 20,739,000 20,489,000 19,694,000 19,887,000 19,670,000 20,821,000 19,660,000 19,692,000 19,287,000 16,674,000 17,693,000 14,785,000 20,656,000 23,476,000 11,662,000 6,790,000 18,248,000   8,776,000 9,833,000 11,432,000 5,962,000 5,200,000 9,547,000 5,962,000 5,200,000 4,745,000 
      service and other revenue
    		10,376,000 14,406,000 13,953,000 7,090,000 8,763,000 11,921,000 13,845,000 13,511,000 11,967,000 10,230,000 10,938,000 10,552,000 8,579,000 8,767,000 8,370,000 8,548,000 8,810,000 5,674,000 6,552,000 6,317,000 6,409,000 5,498,000 4,207,000 4,760,000 5,762,000 4,302,000 3,017,000 3,174,000 2,790,000 3,017,000 3,174,000 2,507,000 
      collaboration and license revenue
    		560,000 153,000 46,000 532,000 771,000 1,696,000 1,872,000 729,000 155,000 146,000 237,000 629,000      121,500 11,246,000 23,000 261,000 408,000   132,000  1,612,000 269,000  1,612,000 269,000 269,000 
      total revenues
    		36,415,000 43,855,000 40,233,000 24,476,000 30,333,000 35,161,000 35,813,000 34,381,000 32,066,000 31,549,000 31,334,000 31,029,000 28,456,000 25,824,000 26,646,000 23,500,000 29,552,000 30,287,000 31,389,000 13,130,000 27,209,000 26,131,000 14,944,000 13,536,000 15,727,000 15,918,000 10,591,000 8,643,000 12,337,000 10,591,000 8,643,000 7,521,000 
      yoy
    		20.05% 24.73% 12.34% -28.81% -5.40% 11.45% 14.29% 10.80% 12.69% 22.17% 17.59% 32.04% -3.71% -14.74% -15.11% 78.98% 8.61% 15.90% 110.04% -3.00% 73.01% 64.16% 41.10% 56.61% 27.48% 50.30% 22.54% 14.92%     
      qoq
    		-16.96% 9.00% 64.38% -19.31% -13.73% -1.82% 4.17% 7.22% 1.64% 0.69% 0.98% 9.04% 10.19% -3.08% 13.39% -20.48% -2.43% -3.51% 139.06% -51.74% 4.13% 74.86% 10.40% -13.93% -1.20% 50.30% 22.54% -29.94% 16.49% 22.54% 14.92%  
      costs of goods sold and services:
    		                                
      cost of product revenue
    		15,140,000 16,543,000 15,379,000 9,295,000 9,764,000 7,843,000 10,554,000 8,851,000 7,145,000 10,025,000 8,342,000 7,236,000 7,033,000 9,631,000 10,511,000 9,921,000 10,746,000 9,916,000 6,387,000 5,416,000 7,480,000 7,961,000 5,513,000 4,455,000 6,186,000 6,683,000 3,277,000 2,945,000 4,248,000 3,277,000 2,945,000 2,773,000 
      cost of service and other revenue
    		5,709,000 7,274,000 7,648,000 3,881,000 4,154,000 5,149,000 5,106,000 5,472,000 5,295,000 4,725,000 5,209,000 4,655,000 4,497,000 3,601,000 5,191,000 4,868,000 4,247,000 4,110,000 2,896,000 2,501,000             
      total costs of goods sold and services
    		20,849,000 23,817,000 23,027,000 13,176,000 13,918,000 12,992,000 15,660,000 14,323,000 12,440,000 14,750,000 13,551,000 11,891,000 11,530,000 11,371,000 15,702,000 14,789,000 14,993,000   7,917,000 10,860,000   6,605,000 8,914,000 9,051,000 4,996,000 4,670,000 6,330,000 4,996,000   
      gross profit
    		15,566,000 20,038,000 17,206,000 11,300,000 16,415,000 22,169,000 20,153,000 20,058,000 19,626,000 16,799,000 17,783,000 19,138,000 16,926,000 12,592,000 10,944,000 8,711,000 14,559,000 16,261,000 21,106,000 5,213,000 16,349,000 15,050,000 7,033,000 6,931,000 6,813,000 6,867,000 5,595,000 3,973,000 6,007,000 5,595,000   
      yoy
    		-5.17% -9.61% -14.62% -43.66% -16.36% 31.97% 13.33% 4.81% 15.95% 33.41% 62.49% 119.70% 16.26% -22.56% -48.15% 67.10% -10.95% 8.05% 200.10% -24.79% 139.97% 119.16% 25.70% 74.45% 13.42% 22.73%       
      qoq
    		-22.32% 16.46% 52.27% -31.16% -25.96% 10.00% 0.47% 2.20% 16.83% -5.53% -7.08% 13.07% 34.42% 15.06% 25.63% -40.17% -10.47% -22.96% 304.87% -68.11% 8.63% 113.99% 1.47% 1.73% -0.79% 22.73% 40.83% -33.86% 7.36%    
      gross margin %
    		42.75% 45.69% 42.77% 46.17% 54.12% 63.05% 56.27% 58.34% 61.21% 53.25% 56.75% 61.68% 59.48% 48.76% 41.07% 37.07% 49.27% 53.69% 67.24% 39.70% 60.09% 57.59% 47.06% 51.20% 43.32% 43.14% 52.83% 45.97% 48.69% 52.83% 0% 0% 
      operating expenses:
    		                                
      research and development
    		7,323,000 8,796,000 8,009,000 9,081,000 10,036,000 8,067,000 8,104,000 8,104,000 6,675,000 6,991,000 7,200,000 5,946,000 4,720,000 5,072,500 6,631,000 6,625,000 7,034,000 7,734,000 5,377,000 4,312,000 6,683,000 6,217,000 3,924,000 4,016,000 4,268,000 4,398,000 4,411,000 3,705,000 3,852,000 4,411,000 3,705,000 3,644,000 
      selling, general and administrative
    		29,770,000 35,136,000 39,062,000 31,353,000 32,457,000 28,591,000 22,908,000 24,135,000 25,993,000 24,172,000 23,595,000 21,591,000 20,883,000 19,272,000 19,966,000 27,045,000 25,712,000 28,423,000 13,451,000 13,102,000 19,455,000 18,766,000 13,352,000 13,429,000 14,273,000 13,953,000 8,846,000 7,579,000 11,512,000 8,846,000 7,579,000 6,691,000 
      impairment
    		19,835,000                                
      total operating expenses
    		56,928,000 44,789,000 54,531,000 48,400,000 42,781,000 36,938,000 31,901,000 33,166,000 33,592,000 33,749,000 31,553,000 28,699,000 26,346,000 34,547,000 47,547,000 33,670,000 32,746,000 36,157,000 18,828,000 17,414,000 26,138,000 24,983,000 17,276,000 17,445,000 18,541,000 18,351,000 13,257,000 11,284,000 15,364,000 13,257,000 15,954,000 14,684,000 
      income from operations
    		-41,362,000 -24,751,000 -37,325,000 -37,100,000 -26,366,000 -14,769,000 -11,748,000 -13,108,000 -13,966,000 -16,950,000 -13,770,000 -9,561,000 -9,420,000 -21,955,000 -36,603,000 -24,959,000 -18,187,000 -19,896,000 2,278,000 -12,201,000 -9,789,000 -9,933,000 -10,243,000 -10,514,000 -11,728,000 -11,484,000 -7,662,000 -7,311,000     
      yoy
    		56.88% 67.59% 217.71% 183.03% 88.79% -12.87% -14.68% 37.10% 48.26% -22.80% -62.38% -61.69% -48.20% 10.35% -1706.80% 104.57% 85.79% 100.30% -122.24% 16.05% -16.53% -13.51% 33.69% 43.81%         
      qoq
    		67.11% -33.69% 0.61% 40.71% 78.52% 25.72% -10.38% -6.14% -17.60% 23.09% 44.02% 1.50% -57.09% -40.02% 46.65% 37.24% -8.59% -973.40% -118.67% 24.64% -1.45% -3.03% -2.58% -10.35% 2.12% 49.88% 4.80%      
      operating margin %
    		-113.59% -56.44% -92.77% -151.58% -86.92% -42.00% -32.80% -38.13% -43.55% -53.73% -43.95% -30.81% -33.10% -85.02% -137.37% -106.21% -61.54% -65.69% 7.26% -92.92% -35.98% -38.01% -68.54% -77.67% -74.57% -72.14% -72.34% -84.59% 0% 0% 0% 0% 
      other income, net:
    		                                
      interest income
    		892,000 1,159,000 1,448,000 2,692,000 3,267,000 3,490,000 3,535,000 3,681,000 3,948,000 4,319,000 4,185,000 3,886,000 3,449,000 2,815,000 1,712,000 552,000 52,000   -108,000 -163,000 -166,000 282,000 42,000 161,000 281,000 30,000 16,000  30,000 16,000  
      change in fair value of contingent liabilities
    		1,501,000 595,000 58,000                              
      other income
    		21,421,000 225,000 -178,000 49,000 61,000 -357,000 5,000 -9,000 206,000 363,000 2,030,000  8,000 614,000 -101,000 -358,000  -213,000 -26,000 -11,000    -68,000 -167,000 139,000 -25,000 -48,000     
      income before income taxes
    		-17,548,000 -22,772,000 -35,997,000 -30,086,000 -23,417,000 -11,636,000 -8,208,000 -9,436,000 -9,812,000 -12,268,000 -7,555,000 -5,829,000 -5,963,000 -18,526,000 -34,992,000 -24,765,000 -18,352,000 -20,094,000 2,092,000 -12,320,000 -10,146,000 -9,944,000 -9,995,000 -10,540,000 -11,734,000        
      income tax provision
    		7,000 -345,000 2,480,000 73,000 2,913,000 8,000 -145,000 -37,000 -260,000 -141,000 -203,000 -235,000 -140,000 -75,000 72,000 137,000 199,000 68,000 111,000 18,000 42,000 123,000 125,000 -23,000 124,000 268,000   22,000    
      net income
    		-17,541,000 -23,117,000 -33,517,000 -30,013,000 -20,504,000 -11,628,000 -8,353,000 -9,473,000 -10,072,000 -12,409,000 -7,758,000 -6,064,000 -6,103,000 -18,581,000 -35,064,000 -24,902,000 -18,153,000 -20,026,000 2,203,000 -12,302,000 -10,104,000 -9,821,000 -9,870,000 -10,563,000 -11,610,000 -10,958,000 -7,657,000 -7,343,000 -9,405,000 -7,657,000 -7,343,000 -7,202,000 
      yoy
    		-14.45% 98.80% 301.26% 216.83% 103.57% -6.29% 7.67% 56.22% 65.03% -33.22% -77.87% -75.65% -66.38% -7.22% -1691.65% 102.42% 79.66% 103.91% -122.32% 16.46% -12.97% -10.38% 28.90% 43.85% 23.44% 43.11% 4.28% 1.96%     
      qoq
    		-24.12% -31.03% 11.67% 46.38% 76.33% 39.21% -11.82% -5.95% -18.83% 59.95% 27.94% -0.64% -67.15% -47.01% 40.81% 37.18% -9.35% -1009.03% -117.91% 21.75% 2.88% -0.50% -6.56% -9.02% 5.95% 43.11% 4.28% -21.92% 22.83% 4.28% 1.96%  
      net income margin %
    		-48.17% -52.71% -83.31% -122.62% -67.60% -33.07% -23.32% -27.55% -31.41% -39.33% -24.76% -19.54% -21.45% -71.95% -131.59% -105.97% -61.43% -66.12% 7.02% -93.69% -37.13% -37.58% -66.05% -78.04% -73.82% -68.84% -72.30% -84.96% -76.23% -72.30% -84.96% -95.76% 
      net loss per common share, basic and diluted
    		-370 -470 -730 -770 -530 -300 -220 -250 -260 -330 -210 -160                     
      weighted-average common shares outstanding, basic and diluted
    		46,979,000 42,639,000 46,060,000 38,893,000 38,718,000 38,367,000 38,449,000 38,338,000 38,126,000 37,594,000 37,657,000 37,494,000 37,326,559 36,990,965 37,004,596 36,922,468 36,850,894 35,997,473  28,312,925 34,434,931 29,589,132  23,213,653 28,179,132 25,090,708 22,070,786 21,890,978 22,422,960 22,070,786 21,890,978 21,788,605 
      grant revenue
    		 78,000 83,000 22,000 60,000 1,055,000 402,000 254,000 274,000 352,000 499,000 156,000 222,000 213,000 282,000 75,000  975,000 1,929,000  2,291,000 4,493,000           
      other lease costs
    		 -26,000 286,000 296,000 288,000 280,000 889,000 927,000 924,000 1,016,000 758,000 1,162,000 776,000 669,000 609,000                  
      impairment and restructuring costs
    		 3,711,000 7,174,000 7,670,000                             
      other income:
    		                                
      change in fair value of contingent consideration
    		   4,273,000 -379,000                            
      impairment and restructuring
    		         1,570,000                       
      restructuring
    		            -33,000 329,000 3,426,000                  
      other expense
    		           -154,000     -217,000    -194,000 155,000 -34,000          
      collaboration revenue
    		            368,000 170,000 301,000 92,000 86,000                
      costs of goods sold:
    		                                
      net income per share
    		            -0.16 -0.49 -0.95 -0.67 -0.49 -0.55 0.07 -0.43 -0.29 -0.32 -0.37 -0.46 -0.41 -0.39 -0.35 -0.34  -0.35 -0.34 -0.33 
      goodwill impairment
    		              8,220,000                  
      impairment expense
    		             8,677,000 8,695,000                  
      cost of collaboration and license revenue
    		                  1,000,000              
      total costs of goods sold, services, and licenses
    		                 14,026,000 10,283,000   11,081,000 7,911,000          
      interest expense
    		                 -104,500 -160,000              
      weighted-average common shares outstanding, basic
    		                  30,139,157    26,627,831          
      weighted-average common shares outstanding, diluted
    		                  31,386,439    26,627,831          
      cost of services and other revenue
    		                    3,380,000 3,120,000 2,398,000 2,150,000 2,728,000 2,368,000 1,719,000 1,725,000 2,082,000 1,719,000 1,725,000 1,576,000 
      product revenue (including related party activity of 126 and 321 for the three months ended september 30, 2020 and 2019, respectively, and 398 and 526 for the nine months ended september 30, 2020 and 2019, respectively
    		                     7,071,250 10,737,000          
      operating expense:
    		                                
      loss before income tax
    		                         -7,479,750 -7,657,000 -7,343,000     
      interest income (expense)
    		                            21,000    
      other (expense) income
    		                                
      reconciliation of net loss to net loss attributable to common stockholders:
    		                                
      accretion of preferred stock to redemption value
    		                                
      accrued dividends on preferred stock
    		                                
      net loss attributable to common stockholders
    		                             -7,657,000 -7,343,000 -7,202,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 
                                      
        assets
      		                                
        current assets:
      		                                
        cash and cash equivalents
      		36,182,000 29,839,000 38,298,000 132,896,000 76,508,000 56,709,000 29,339,000 47,002,000 45,281,000 174,422,000 201,261,000 329,525,000 329,354,000 338,740,000 343,743,000 361,293,000 374,317,000 396,465,000 410,747,000 430,780,000 442,672,000 181,584,000 173,162,000 88,806,000 96,359,000 109,155,000 113,327,000 72,025,000 33,972,000 51,423,000 60,474,000 65,231,000 
        marketable securities
      		63,083,000 88,393,000 96,511,000 128,276,000 190,369,000 232,413,000 264,184,000 249,853,000 256,640,000 146,902,000 126,449,000                      
        accounts receivable
      		26,776,000 29,972,000 33,029,000 23,549,000 28,258,000 32,141,000 31,089,000 31,784,000 29,276,000 25,414,000 24,083,000 24,423,000 22,546,000 19,017,000 18,330,000 19,683,000 22,616,000 23,786,000 18,434,000 15,430,000 14,936,000 17,184,000 26,262,000 9,526,000 12,065,000 10,906,000 11,914,000 9,134,000 7,303,000 4,648,000 3,586,000 4,661,000 
        inventory
      		50,959,000 54,763,000 54,957,000 30,142,000 31,028,000 32,775,000 32,969,000 28,363,000 26,015,000 22,365,000 19,945,000 18,156,000 17,070,000 16,786,000 18,236,000 21,985,000 22,669,000 22,190,000 22,794,000 21,225,000 17,044,000 14,856,000 13,274,000 13,789,000 11,392,000 10,463,000 11,161,000 8,850,000 7,742,000 5,375,000 5,486,000 5,332,000 
        prepaid expenses and other current assets
      		8,725,000 9,290,000 10,483,000 7,254,000 8,839,000 9,556,000 9,378,000 8,724,000 9,551,000 9,291,000 9,273,000 6,954,000 7,002,000 6,860,000 6,475,000 10,237,000 14,104,000 6,514,000 7,454,000 9,005,000 7,791,000 5,981,000 2,230,000 2,117,000 2,722,000 2,137,000 2,297,000 2,377,000 2,502,000 1,255,000 1,152,000 1,393,000 
        total current assets
      		185,725,000 212,257,000 233,278,000 322,117,000 335,002,000 363,594,000 366,960,000 365,726,000 366,763,000 378,394,000 381,011,000 379,058,000 375,972,000 381,403,000 386,784,000 413,198,000 433,706,000 448,955,000 459,429,000 476,440,000 482,443,000 219,605,000 214,928,000 114,238,000 122,538,000 132,661,000 138,699,000 92,386,000 51,519,000 62,701,000 70,698,000 76,617,000 
        restricted cash
      		3,344,000 3,341,000 3,336,000 2,641,000 2,639,000 2,610,000 2,609,000 2,607,000 2,605,000 2,604,000 2,647,000 2,686,000 2,920,000 2,597,000 2,596,000 2,594,000 2,577,000 2,577,000 1,658,000 1,400,000 1,400,000 1,000,000 1,000,000 1,000,000 1,000,000 1,026,000 1,026,000 1,026,000 1,019,000 1,000,000   
        property and equipment
      		21,369,000 23,672,000 25,765,000 15,748,000 16,457,000 17,150,000 17,662,000 18,205,000 17,492,000 17,926,000 17,517,000 18,328,000 19,056,000 20,162,000 21,441,000 22,295,000 19,683,000 17,960,000 16,466,000 15,778,000 14,183,000 13,912,000 12,827,000 12,353,000 11,992,000 12,047,000 12,064,000 12,082,000 8,582,000 2,836,000 2,406,000 2,234,000 
        intangible assets
      		109,161,000 131,787,000 135,148,000 16,332,000 16,520,000 4,031,000 4,782,000 4,981,000 5,339,000 6,034,000 6,003,000 6,476,000 7,129,000 7,516,000 7,511,000 8,527,000 9,692,000 10,534,000 11,374,000 12,174,000 12,464,000 13,716,000 13,242,000 13,310,000 13,115,000 14,307,000 14,221,000 2,054,000 2,198,000 2,512,000 2,676,000 2,841,000 
        goodwill
      		26,710,000 26,376,000 23,460,000  6,574,000           8,675,000 9,323,000 9,632,000 9,903,000 10,121,000 9,933,000 10,460,000 9,714,000 9,390,000 8,914,000 9,353,000 8,961,000 1,308,000 1,308,000 1,308,000 1,308,000 1,308,000 
        operating lease right-of-use assets
      		15,861,000 16,664,000 18,184,000 15,710,000 15,971,000 16,339,000 16,876,000 17,399,000 17,748,000 18,251,000 19,860,000 20,380,000                     
        other non-current assets
      		4,502,000 4,669,000 4,052,000 3,061,000 3,349,000 2,809,000 2,137,000 2,370,000 1,802,000 1,802,000 2,004,000 2,282,000 1,345,000 1,298,000 1,200,000 377,000 378,000 378,000 384,000 377,000 373,000 357,000 375,000 529,000 525,000 557,000 574,000 552,000 550,000 836,000 684,000 683,000 
        total assets
      		366,672,000 418,766,000 444,140,000 375,609,000 396,512,000 406,533,000 411,026,000 411,288,000 411,749,000 425,011,000 429,042,000 429,210,000 427,313,000 434,199,000 446,697,000 488,601,000 504,657,000 501,527,000 510,840,000 528,044,000 532,666,000 271,045,000 264,105,000 162,940,000 170,305,000 169,951,000 175,545,000 109,408,000 65,176,000 71,193,000 77,772,000 83,683,000 
        liabilities and stockholders' equity
      		                                
        current liabilities:
      		                                
        accounts payable
      		8,657,000 13,568,000 10,633,000 9,124,000 6,731,000 6,953,000 6,378,000 7,273,000 3,914,000 5,048,000 4,786,000 3,238,000 2,585,000 3,836,000 2,106,000 5,983,000 4,262,000 9,209,000 5,824,000 6,862,000 6,503,000 6,799,000 5,962,000 4,878,000 4,723,000 5,777,000 4,245,000 3,510,000 3,789,000 3,866,000 3,117,000 2,963,000 
        accrued compensation and benefits
      		9,850,000 14,979,000 12,582,000 9,110,000 6,308,000 12,620,000 9,860,000 9,044,000 6,706,000 13,659,000 9,775,000 7,525,000 4,880,000 10,658,000 10,503,000 10,638,000 8,139,000 13,252,000 9,176,000 8,919,000 7,015,000 10,777,000 7,038,000 5,375,000 4,292,000 6,570,000 5,251,000 4,150,000 3,480,000 3,404,000 2,312,000 1,942,000 
        accrued expenses and other current liabilities
      		8,275,000 17,571,000 24,812,000 15,388,000 13,314,000 8,851,000 6,591,000 6,577,000 7,021,000 6,041,000 6,672,000 6,777,000                     
        deferred revenue
      		15,190,000 20,728,000 20,913,000 9,427,000 9,102,000 8,827,000 8,984,000 10,121,000 10,234,000 9,468,000 9,827,000 10,421,000 10,682,000 8,644,000 8,976,000 12,157,000 9,194,000 6,361,000 5,743,000 6,149,000 6,420,000 5,421,000 3,793,000 5,019,000 5,438,000 4,697,000 4,909,000 5,186,000 5,484,000 4,755,000 6,141,000 5,842,000 
        operating lease liabilities
      		7,933,000 7,916,000 7,984,000 5,153,000 4,940,000 4,756,000 4,641,000 4,524,000 4,366,000 4,241,000 4,093,000 3,986,000                     
        total current liabilities
      		49,905,000 74,762,000 77,352,000 48,202,000 40,395,000 42,007,000 36,454,000 37,539,000 32,241,000 38,457,000 35,153,000 31,947,000 26,937,000 30,958,000 28,571,000 36,669,000 31,773,000 36,977,000 31,190,000 37,675,000 36,491,000 39,803,000 28,092,000 18,897,000 18,010,000 19,833,000 18,223,000 17,018,000 16,598,000 15,242,000 23,356,000 22,790,000 
        deferred revenue, net of current portion
      		2,795,000 5,830,000 7,341,000 1,056,000 1,098,000 1,073,000 884,000 928,000 933,000 1,227,000 1,126,000 1,304,000 1,419,000 1,415,000 1,591,000 1,531,000 1,222,000 1,099,000 929,000 740,000 776,000 577,000 363,000 384,000 396,000 466,000 357,000 374,000 431,000 598,000 1,135,000 1,434,000 
        operating lease liabilities, net of current portion
      		27,403,000 29,323,000 31,212,000 30,381,000 31,467,000 32,615,000 33,850,000 35,052,000 36,084,000 37,223,000 38,306,000 39,378,000                     
        non-current portion of contingent liabilities
      		3,547,000 5,024,000 5,904,000                              
        other non-current liabilities
      		883,000 8,097,000 7,301,000 794,000 822,000 800,000 956,000 1,017,000 1,053,000 1,177,000 1,105,000 1,225,000 1,216,000 1,469,000 1,570,000 1,810,000 1,691,000    2,378,000 2,649,000 2,543,000 2,537,000 2,504,000 13,407,000 13,165,000 9,727,000 6,360,000 79,000 106,000 128,000 
        total liabilities
      		84,533,000 123,036,000 129,606,000 83,151,000 80,119,000 76,495,000 72,144,000 74,536,000 70,311,000 78,084,000 75,690,000 73,854,000 69,981,000 75,259,000 73,928,000   60,575,000 55,326,000 62,034,000 61,197,000 64,920,000 55,064,000 51,906,000 51,259,000 41,293,000 39,310,000 34,663,000 30,961,000 23,505,000 24,597,000 24,352,000 
        commitments and contingencies
      		                                
        stockholders’ equity:
      		                                
        common stock: 0.001 par value...
      		47,000  47,000                              
        additional paid-in capital
      		877,877,000 873,637,000 869,420,000 813,945,000 808,760,000 803,160,000 798,707,000 793,906,000 789,006,000 783,142,000 778,615,000 772,473,000 768,141,000 763,688,000 759,312,000 756,139,000 750,742,000 745,936,000 739,862,000 734,170,000 728,128,000 451,433,000 446,228,000 351,188,000 348,072,000 345,027,000 342,628,000 270,136,000 219,045,000 214,220,000 212,050,000 210,863,000 
        accumulated other comprehensive loss
      		-1,013,000 -723,000 -818,000 -928,000 -1,821,000 -3,080,000 -1,411,000 -3,151,000 -3,038,000 -1,757,000 -3,214,000 -2,825,000            -26,000 -1,200,000 -153,000 -1,135,000      
        accumulated deficit
      		-594,772,000 -577,231,000 -554,115,000 -520,598,000 -490,585,000 -470,081,000 -458,453,000 -454,041,000 -444,568,000 -434,496,000 -422,087,000 -414,329,000 -408,265,000 -402,162,000 -383,581,000 -348,517,000 -323,615,000 -305,462,000 -285,436,000 -269,775,000 -257,878,000 -247,774,000 -237,953,000 -240,156,000 -227,854,000 -216,244,000 -205,286,000 -195,416,000     
        total stockholders’ equity
      		282,139,000 295,730,000 314,534,000 292,458,000 316,393,000 330,038,000 338,882,000 336,752,000 341,438,000 346,927,000 353,352,000 355,356,000 357,332,000 358,940,000 372,769,000 405,456,000 426,408,000 440,952,000 455,514,000 466,010,000 471,469,000 206,125,000 209,041,000 111,034,000 119,046,000 128,658,000 136,235,000 74,745,000 34,215,000 47,688,000 53,175,000 59,331,000 
        total liabilities and stockholders’ equity
      		366,672,000 418,766,000 444,140,000 375,609,000 396,512,000 406,533,000 411,026,000 411,288,000 411,749,000 425,011,000 429,042,000 429,210,000 427,313,000 434,199,000 446,697,000 488,601,000 504,657,000 501,527,000 510,840,000 528,044,000 532,666,000 271,045,000 264,105,000 162,940,000 170,305,000 169,951,000 175,545,000 109,408,000 65,176,000 71,193,000 77,772,000 83,683,000 
        common stock, 0.001 par value per share...
      		                                
        authorized: 120,000 shares; issued and outstanding: 46,744 and 38,573 shares at december 31, 2025 and 2024, respectively
      		 47,000                               
        financing lease right-of-use assets
      		  917,000                              
        financing lease liabilities
      		  428,000                              
        financing lease liabilities, net of current portion
      		  496,000                              
        non-current portion of contingent consideration
      		   2,718,000 6,337,000                            
        common stock: 0.001 par value per share...
      		   39,000 39,000  39,000 38,000                         
        authorized: 120,000 shares; issued and outstanding: 38,544 and 38,014 shares at december 31, 2024 and 2023, respectively
      		     39,000                           
        authorized: 120,000 shares; issued and outstanding: 38,353 and 38,014 shares at march 31, 2024 and december 31, 2023, respectively
      		        38,000                        
        authorized: 120,000 shares; issued and outstanding: 38,014 and 37,280 shares at december 31, 2023 and 2022, respectively
      		         38,000                       
        common stock, 0.001 par value...
      		                                
        authorized shares: 120,000; issued and outstanding: 37,839 and 37,280 shares at september 30, 2023 and december 31, 2022, respectively
      		          38,000                      
        authorized shares: 120,000; issued and outstanding: 37,566 and 37,280 shares at june 30, 2023 and december 31, 2022, respectively
      		           37,000                     
        right-of-use assets
      		            20,891,000 21,223,000 27,165,000 32,935,000 29,298,000 11,491,000 11,626,000 11,754,000 11,870,000 11,995,000 12,019,000 12,120,000 12,221,000        
        liabilities and stockholders’ equity
      		                                
        other accrued expenses
      		            4,624,000 4,747,000 5,951,000 4,799,000 8,024,000 6,486,000 5,875,000 5,083,000 5,603,000 4,845,000 4,177,000 2,597,000 3,068,000 2,498,000 3,539,000 4,019,000 3,744,000 3,217,000 4,181,000 3,580,000 
        short-term lease liabilities
      		            3,875,000  767,000                  
        other current liabilities
      		            291,000 386,000 268,000 396,000 268,000 241,000 1,205,000 1,624,000 1,985,000 3,054,000 212,000 299,000 184,000 216,000 204,000 78,000 26,000    
        long-term lease liabilities
      		            40,409,000  42,196,000                  
        common stock
      		                                
        authorized shares: 120,000,000 at march 31, 2023 and december 31, 2022, respectively; issued and outstanding: 37,423,981 shares and 37,279,994 shares at march 31, 2023 and december 31, 2022, respectively
      		            37,000                    
        accumulated other comprehensive income
      		            -2,581,000 -2,623,000 -2,999,000 -2,203,000 -756,000 441,000 1,051,000 1,578,000 1,183,000 2,434,000 734,000          
        short term lease liabilities
      		             2,687,000  2,696,000 1,886,000 1,428,000 1,374,000 1,322,000 1,271,000 1,234,000 1,166,000 729,000 305,000        
        long term lease liabilities
      		             41,417,000  43,135,000 43,563,000 20,464,000 20,845,000 21,210,000 21,552,000 21,891,000 22,159,000 22,458,000 22,741,000        
        authorized shares: 120,000,000 at december 31, 2022 and december 31, 2021, respectively; issued and outstanding: 37,279,994 shares and 36,768,035 shares at december 31, 2022 and december 31, 2021, respectively
      		             37,000                   
        authorized shares: 120,000,000 at september 30, 2022 and december 31, 2021, respectively; issued and outstanding: 37,093,601 shares and 36,768,035 shares at september 30, 2022 and december 31, 2021, respectively
      		              37,000                  
        authorized—120,000,000 shares as of june 30, 2022 and december 31, 2021; issued and outstanding — 36,974,827 and 36,768,035 shares as of june 30, 2022 and december 31, 2021, respectively
      		               37,000                 
        authorized—120,000,000 shares as of march 31, 2022 and december 31, 2021; issued and outstanding — 36,899,156 and 36,768,035 shares as of march 31, 2022 and december 31, 2021, respectively
      		                37,000                
        current portion of long term debt
      		                  1,993,000 7,716,000 7,694,000 7,673,000 5,744,000   75,000 75,000 75,000 75,000  7,605,000 8,463,000 
        deferred tax liabilities
      		                 2,035,000 2,362,000 2,409,000             
        authorized—120,000,000 shares as of december 31, 2021 and december 31, 2020; issued and outstanding — 36,768,035 and 31,796,544 shares as of december 31, 2021 and december 31, 2020, respectively
      		                 37,000               
        authorized—120,000,000 shares as of september 30, 2021 and december 31, 2020; issued and outstanding — 36,574,132 and 31,796,544 shares as of september 30, 2021 and december 31, 2020, respectively
      		                  37,000              
        authorized—120,000,000 shares as of june 30, 2021 and december 31, 2020; issued and outstanding — 36,454,369 and 31,796,544 shares as of june 30, 2021 and december 31, 2020, respectively
      		                   37,000             
        authorized—120,000,000 shares as of march 31, 2021 and december 31, 2020; issued and outstanding — 36,294,928 and 31,796,544 shares as of march 31, 2021 and december 31, 2020, respectively
      		                    36,000            
        long term debt, net of current portion
      		                      1,907,000 7,630,000 7,608,000 7,587,000 7,565,000 7,544,000 7,572,000 7,586,000   
        authorized—120,000,000 shares as of december 31, 2020 and december 31, 2019; issued and outstanding — 31,796,544 and 28,112,201 shares as of december 31, 2020 and december 31, 2019, respectively
      		                     32,000           
        authorized—120,000,000 shares as of september 30, 2020 and december 31, 2019; issued and outstanding — 31,583,509 and 28,112,201 shares as of september 30, 2020 and december 31, 2019, respectively
      		                      32,000          
        authorized—120,000,000 shares as of june 30, 2020 and december 31, 2019; issued and outstanding — 28,381,280 and 28,112,201 shares as of june 30, 2020 and december 31, 2019, respectively
      		                       28,000         
        authorized—120,000,000 shares as of march 31, 2020 and december 31, 2019; issued and outstanding — 28,243,442 and 28,112,201 shares as of march 31, 2020 and december 31, 2019, respectively
      		                        28,000        
        authorized—120,000,000 shares as of december 31, 2019 and december 31, 2018; issued and outstanding — 28,112,201 and 22,369,036 shares as of december 31, 2019 and december 31, 2018, respectively
      		                         28,000       
        authorized—120,000,000 shares as of september 30, 2019 and december 31, 2018; issued and outstanding — 27,967,713 and 22,369,036 shares as of september 30, 2019 and december 31, 2018, respectively
      		                          28,000      
        authorized—120,000,000 shares as of june 30, 2019 and december 31, 2018; issued and outstanding — 24,894,019 and 22,369,036 shares as of june 30, 2019 and december 31, 2018, respectively
      		                           25,000     
        authorized—120,000,000 shares as of march 31, 2019 and december 31, 2018; issued and outstanding—22,491,447 and 22,369,036 shares as of march 31, 2019 and december 31, 2018, respectively
      		                            23,000    
        preferred stock`, 0.001 par value:
      		                                
        authorized—5,000,000 shares as of september 30, 2018 and december 31, 2017; no shares issued or outstanding as of september 30, 2018 and december 31, 2017
      		                                
        authorized—120,000,000 shares as of september 30, 2018 and december 31, 2017; issued and outstanding—22,151,410 and 21,707,041 shares as of september 30, 2018 and december 31, 2017, respectively
      		                             22,000   
        authorized—5,000,000 shares as of june 30, 2018 and december 31, 2017; no shares issued or outstanding as of june 30, 2018 and december 31, 2017
      		                                
        authorized—120,000,000 shares as of june 30, 2018 and december 31, 2017; issued and outstanding—21,980,681 and 21,707,041 shares as of june 30, 2018 and december 31, 2017, respectively
      		                              22,000  
        authorized—5,000,000 shares as of march 31, 2018 and december 31, 2017; no shares issued or outstanding as of march 31, 2018 and december 31, 2017
      		                                
        authorized—120,000,000 shares as of march 31, 2018 and december 31, 2017; issued and outstanding—21,823,282 and 21,707,041 shares as of march 31, 2018 and december 31, 2017, respectively
      		                               22,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 
                                        
          cash flows from operating activities:
        		                                
          net loss
        		-17,541,000 -23,117,000 -33,516,000 -30,013,000 -20,504,000 -11,628,000 -7,358,000 -9,473,000 -10,072,000 -12,409,000 -7,758,000 -6,064,000 -6,103,000 -18,581,000 -35,064,000 -24,902,000 -18,153,000 -20,026,000 -15,661,000 -11,897,000 -10,104,000   -12,302,000 -11,610,000 -10,958,000 -9,870,000 -10,563,000 -9,405,000  -7,343,000 -7,202,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                
          depreciation and amortization expense
        		5,603,000 6,226,000 5,431,000 1,999,000 2,188,000 1,723,000 1,616,000 1,601,000 1,523,000 1,576,000 1,943,000 1,406,000 1,439,000 1,163,000 1,396,000 1,432,000 1,358,000 1,285,000 1,222,000 1,193,000 1,151,000 1,125,000 1,108,000 1,033,000 1,046,000 821,000 1,235,000 544,000 409,000 411,000 337,000 272,000 
          credit losses on accounts receivable
        		305,000 344,000 546,000 -315,000 53,000 -156,000 68,000 500,000 176,000 25,000 -13,000                      
          accretion of marketable securities
        		-150,000 -227,000 -284,000 -588,000 -979,000 -1,516,000 -1,698,000 -1,962,000 -1,657,000                        
          operating lease right-of-use asset amortization
        		797,000 1,023,000 1,208,000 289,000 561,000 522,000 531,000 362,000 478,000 497,000 516,000                      
          stock-based compensation expense
        		4,528,000 4,415,000 5,469,000 5,372,000 5,462,000 4,837,000 4,657,000 5,228,000 5,265,000 4,326,000 4,343,000 4,193,000 3,902,000 3,663,000 2,766,000 5,186,000 3,827,000 4,931,000 4,008,000 3,650,000 3,386,000 3,129,000 2,360,000 2,501,000 2,109,000 1,675,000 1,828,000 1,601,000 1,284,000 1,867,000 890,000 636,000 
          impairment
        		19,835,000 483,000                               
          change in fair value of contingent liabilities
        		-1,501,000 -595,000                               
          recognition of off-market liability
        		-13,975,000                                
          other operating activity
        		15,000 -464,000 294,000 42,000 -412,000 444,000 -376,000 -68,000 55,000                        
          changes in assets and liabilities:
        		                                
          accounts receivable
        		2,717,000 2,708,000 -1,575,000 5,147,000 4,329,000 -1,302,000 840,000 -3,009,000 -4,233,000 -1,080,000 135,000 -2,077,000 -3,673,000 111,000 1,566,000 2,160,000 1,319,000 -5,297,000 -3,296,000 -487,000 2,227,000 9,120,000 -16,805,000 2,619,000 -1,174,000 1,109,000 -2,178,000   -1,063,000 1,075,000 1,148,000 
          inventory
        		3,221,000 -171,000 1,211,000 908,000 2,085,000 166,000 -834,000 -2,341,000 -3,670,000 -2,398,000 -1,785,000 -1,092,000 -89,000 1,467,000 3,739,000 664,000 -484,000 341,000 -1,638,000 -4,466,000 -2,327,000 -1,614,000 -1,000 -2,106,000 -1,398,000 496,000 -1,038,000      
          prepaid expenses and other current assets
        		453,000 1,323,000 256,000 1,521,000 421,000 -275,000 -765,000 851,000 -254,000 458,000 -2,302,000                      
          accounts payable
        		-4,846,000 3,009,000 -6,333,000 2,397,000 399,000 135,000 -1,466,000 3,176,000 -1,122,000 241,000 1,579,000 640,000 -1,271,000 1,723,000 -3,865,000 2,086,000 -5,306,000 3,386,000 -1,012,000 2,149,000 -2,109,000 836,000 772,000 186,000 -1,145,000 1,456,000 765,000      
          accrued compensation and benefits, accrued expenses, and other current liabilities
        		-7,254,000 -2,067,000 -7,452,000 5,122,000 -3,517,000 4,564,000 1,224,000 1,736,000 -6,126,000 3,400,000 2,202,000                      
          deferred revenue
        		-8,572,000  -1,109,000 284,000 299,000 32,000 -1,180,000 -118,000 472,000 -259,000 -772,000 -375,000 2,041,000 -509,000 -3,120,000 3,272,000 2,956,000 788,000 -217,000 -306,000 1,197,000 1,842,000 -1,248,000 -430,000 671,000 -104,000 -294,000 -355,000 45,000    
          net change in other operating assets and liabilities
        		-1,742,000                                
          net cash from operating activities
        		-18,107,000 -16,444,000 -41,249,000 -5,655,000 -13,888,000 -4,302,000 -5,747,000 -4,951,000 -20,164,000 -5,984,000 -4,049,000 633,000 -9,502,000 -4,090,000 -14,547,000 -7,940,000 -21,695,000 -10,292,000 -13,777,000 -9,749,000 -14,089,000 4,654,000 -7,419,000 -7,421,000 -13,179,000 -4,535,000 -8,832,000      
          capital expenditures
        		-87,000 98,000 -953,000 -794,000 -734,000 -412,000 -1,031,000 -859,000 -284,000 -2,216,000 -788,000 -648,000 11,000 -1,595,000 -3,677,000 -5,060,000 -1,394,000 -2,530,000 -3,824,000 -9,712,000 3,262,000 -1,110,000 -465,000 -1,002,000 -324,000 -603,000 -1,014,000      
          free cash flows
        		-18,194,000 -16,346,000 -42,202,000 -6,449,000 -14,622,000 -4,714,000 -6,778,000 -5,810,000 -20,448,000 -8,200,000 -4,837,000 -15,000 -9,491,000 -5,685,000 -18,224,000 -13,000,000 -23,089,000 -12,822,000 -17,601,000 -19,461,000 -10,827,000 3,544,000 -7,884,000 -8,423,000 -13,503,000 -5,138,000 -9,846,000      
          cash flows from investing activities:
        		                                
          purchases of marketable securities
        		  -15,413,000 1,000 -30,246,000  -81,628,000 -51,455,000 -137,889,000                        
          proceeds from sales and maturities of marketable securities
        		25,350,000 32,440,000 47,515,000 62,613,000 73,261,000                            
          purchases of property and equipment
        		-87,000 98,000 -677,000 -777,000 -1,256,000 -412,000 -851,000 -1,599,000 -506,000 -2,216,000 -788,000 -648,000 -136,000 -1,595,000 -3,677,000 -5,060,000 -1,394,000 -2,453,000 -3,824,000 -7,260,000 -79,000 -1,781,000 -788,000 -935,000 -426,000 -544,000 -473,000      
          acquisitions, net of cash acquired
        		 0                        0       
          net cash from investing activities
        		25,263,000 8,439,000 -52,850,000 61,880,000 32,762,000 32,384,000 -12,429,000 6,975,000 -109,195,000 -21,629,000 -125,988,000 -648,000 -136,000 -1,595,000 -3,677,000 -5,060,000 -874,000 -2,194,000 -2,015,000 -4,564,000 2,435,000 1,523,000 -788,000 -935,000 -426,000 -544,000 -15,002,000 -3,913,000 -5,917,000    
          cash flows from financing activities:
        		                                
          deferred acquisition payment
        		-1,000,000                                
          principal payments on financing leases
        		-83,000                                
          proceeds from common stock issued under stock plans
        		340,000 -192,000 262,000 0 668,000 67,000 578,000 384,000 2,037,000 257,000 1,855,000                      
          payments for employee taxes withheld on stock-based compensation awards
        		-27,000 -436,000 -6,000 -429,000 -575,000 -26,000 -434,000 -712,000 -1,438,000 -56,000 -55,000                      
          net cash from financing activities
        		-770,000 -522,000 150,000 -429,000 93,000 41,000 144,000 -328,000 599,000 201,000 1,800,000 139,000 551,000 714,000 407,000 211,000 979,000 -851,000 -4,060,000 2,393,000 273,313,000 2,076,000 92,684,000 615,000 861,000 724,000 65,201,000      
          net increase in cash, cash equivalents, and restricted cash
        		6,386,000  -93,949,000 55,796,000 18,967,000                            
          effect of exchange rate changes on cash, cash equivalents, and restricted cash
        		-40,000 73,000 46,000 594,000 861,000 -752,000 371,000 27,000 -380,000 530,000 -66,000                      
          cash, cash equivalents, and restricted cash at beginning of period
        		33,180,000 0 0 0 59,319,000 0 0 0 177,026,000 0 0                      
          cash, cash equivalents, and restricted cash at end of period
        		39,526,000 -8,454,000 -93,903,000 56,390,000 79,147,000 27,371,000 -17,661,000 1,723,000 47,886,000 -26,882,000 -128,303,000                      
          deferred taxes
        		 -189,000           207,000                    
          other non-current assets
        		 142,000 257,000 355,000 -502,000 -736,000 117,000 -575,000 -21,000 -59,000 249,000 -932,000 -33,000 -50,000 -861,000 1,000 1,000 1,000 17,000 -4,000 -16,000 16,000 155,000 -5,000 32,000 0 -23,000 -1,000 3,000    
          purchases of marketable debt securities
        		                                
          net decrease in cash, cash equivalents, and restricted cash
        		     28,123,000 -18,032,000 1,696,000 -128,760,000  -128,237,000                      
          supplemental disclosure of cash flow information:
        		                                
          common stock issued in exchange for acquisition of akoya
        		                                
          purchases of property and equipment in accounts payable and accruals
        		                                
          operating lease liabilities
        		  -1,945,000 -901,000 -1,157,000 -1,104,000 -1,095,000 -888,000 -988,000 -955,000 -960,000 -909,000 179,000 890,000 1,972,000 -3,041,000 -87,000 -328,000 -312,000 -283,000 -307,000 -199,000 128,000 134,000 253,000        
          other non-current liabilities
        		  1,134,000 625,000 -2,993,000 -8,000 -28,000 29,000 10,000 54,000 -35,000 131,000 -203,000 -118,000 137,000 262,000 -271,000 -255,000   -107,000 -311,000 260,000 -260,000 -177,000 -223,000 620,000 3,366,000 6,082,000    
          equity consideration transferred in connection with the acquisition of akoya
        		                                
          cash paid for taxes
        		  405,000 385,000 505,000 172,000 189,000 339,000 175,000 89,000 217,000                      
          right-of-use assets obtained in exchange for lease liabilities
        		                                
          purchases of property and equipment in accounts payable and accrued expenses
        		  -276,000 -17,000 522,000  -180,000 740,000 222,000                        
          impairment of goodwill
        		                                
          change in fair value of contingent consideration
        		   -4,273,000 379,000                            
          acquisition, net of cash acquired
        		   43,000 -8,997,000                            
          right-of-use asset obtained in exchange for lease liabilities
        		             255,000   18,156,000                
          proceeds from maturities of marketable securities
        		     57,430,000 70,050,000 60,029,000 29,200,000                        
          proceeds from radx grant on assets purchased
        		             0 0 0 520,000 259,000 1,809,000 2,696,000 2,514,000            
          operating lease right-of-use assets obtained in exchange for lease liabilities
        		                                
          non-cash consideration received under product sales agreement
        		                                
          shares received as consideration under product sales agreement
        		          -225,000                      
          proceeds from marketable debt securities
        		                                
          sale of common stock in underwritten public offering
        		                 0 0 0 269,718,000 0           
          payments on notes payable
        		                 -1,994,000    0 0 0 -75,000 0 0      
          cash paid for interest
        		                 0 80,000 155,000 154,000 157,000 313,000 0 155,000 178,000 318,000 0 160,000 159,000 166,000 181,000 
          foreign currency losses
        		          154,000                      
          unrealized losses on marketable securities
        		                                
          amortization of (discount) premium on marketable securities
        		                                
          deferred income taxes
        		          -101,000                      
          loss on disposal of fixed assets
        		                      51,000 0 69,000 116,000 10,000      
          operating activities
        		                                
          credit loss expense on accounts receivable
        		            110,000 -403,000 -479,000 752,000 -171,000 -73,000 266,000 0 20,000            
          unrealized losses on foreign currency transactions
        		            63,000                    
          non-cash operating lease expense
        		            334,000                    
          changes in operating assets and liabilities:
        		                                
          prepaid expenses and other assets
        		            -422,000 -306,000 -1,192,000 3,000,000 -2,070,000 1,002,000 1,557,000 -1,208,000 -1,744,000 -3,922,000 -121,000 611,000 -495,000 393,000 -406,000 160,000 142,000    
          accrued compensation and benefits, other accrued expenses and other current liabilities
        		            -5,983,000 -955,000 1,366,000 534,000 -4,921,000 3,798,000 1,188,000 1,673,000 -5,598,000 4,102,000 3,125,000 702,000 -1,710,000 249,000 -96,000      
          investing activities
        		                                
          financing activities
        		                                
          proceeds from stock options exercised
        		            13,000 714,000 120,000 211,000 385,000 1,143,000 1,138,000 2,393,000 3,076,000 2,076,000 832,000 615,000 496,000 644,000 266,000 1,407,000 503,000 303,000 297,000 84,000 
          proceeds from espp purchase
        		            551,000 0 287,000 0 594,000 0 546,000 0 519,000 0 448,000 0 440,000 80,000 406,000 65,000 328,000    
          payments for employee taxes on units withheld
        		            -13,000                    
          net increase in cash, cash equivalents and restricted cash
        		            -9,087,000  -17,817,000 -12,789,000 -21,590,000                
          effect of foreign currency exchange rate on cash
        		            24,000 -31,000 269,000 -218,000 -558,000 -26,000 77,000 28,000 -171,000 169,000 -121,000 188,000 -78,000 183,000       
          cash, cash equivalents and restricted cash at beginning of period
        		            341,337,000                    
          cash, cash equivalents and restricted cash at end of period
        		            332,274,000                    
          cash paid for income taxes
        		            246,000                    
          noncash transactions:
        		                                
          purchases of property and equipment included in accounts payable and accrued expenses
        		            147,000                    
          reconciliation of cash, cash equivalents and restricted cash:
        		                                
          cash and cash equivalents
        		            329,354,000 -5,003,000 -17,550,000 -13,024,000 374,317,000 -14,282,000 -20,033,000 -11,892,000 442,672,000 8,422,000 84,356,000 -7,553,000 96,359,000 -4,172,000 41,302,000 38,053,000 33,972,000    
          restricted cash
        		            2,920,000 1,000 2,000 17,000 2,577,000 919,000 258,000 0 1,400,000 0 0 0 1,000,000 0 0 7,000 1,019,000    
          total cash, cash equivalents, and restricted cash
        		            332,274,000 -5,002,000 -17,548,000 -13,007,000 376,894,000 -13,363,000 -19,775,000 -11,892,000 444,072,000 8,422,000 84,356,000 -7,553,000 97,359,000 -4,172,000 41,302,000 38,060,000 34,991,000    
          inventory step-up amortization
        		                 0 0 111,000 164,000 52,000 476,000 -244,000 438,000        
          non-cash lease expense
        		                                
          goodwill impairment
        		             0                   
          impairment of long-lived assets
        		                                
          non-cash interest expense
        		                 0 22,000 21,000 22,000 21,000 22,000 21,000 22,000 21,000 22,000 22,000 24,000 34,000 46,000 53,000 
          net increase in cash and cash equivalents
        		                 -13,337,000 -19,852,000 -11,920,000 261,659,000 8,253,000 84,477,000   -4,355,000 41,367,000      
          cash, restricted cash, and cash equivalents at beginning of period
        		               0 399,042,000 0 0 0 182,584,000 0 0 0 110,181,000 0 0 0 45,429,000    
          cash, restricted cash, and cash equivalents at end of period
        		               -13,007,000 376,894,000 -13,363,000 -19,775,000 -11,892,000 444,072,000 8,422,000 84,356,000 -7,553,000 97,359,000 -4,172,000 41,302,000 38,060,000 34,991,000    
          supplemental cash flow information
        		                                
          purchases of property and equipment included in accounts payable and other accrued expenses
        		                 -77,000               
          reconciliation of cash, cash equivalents, and restricted cash:
        		                                
          impairment expense
        		                                
          other non-cash items
        		                                
          cash, cash equivalents and restricted stock at beginning of period
        		                                
          cash, cash equivalents and restricted stock at end of period
        		                                
          reduction in the carrying amount of right-of-use assets
        		               577,000 348,000                
          contract acquisition costs
        		               71,000 -41,000 -69,000 -51,000 0 -72,000 186,000 0 11,000 -110,000 -197,000 593,000      
          reduction in the carrying amounts of right-of-use assets
        		                 135,000 118,000 118,000 128,000 41,000 96,000          
          sale of common stock in at-the-market offering
        		                                
          purchase of property and equipment included in other non-current liabilities
        		                                
          common stock issued in connection with the acquisition of umandiagnostics ab
        		                                
          deferred tax liabilities
        		                                
          purchases of property and equipment included in accounts payable
        		                   -2,452,000 3,341,000 671,000 323,000 -67,000 102,000 119,000 -234,000 268,000 11,000    
          net income
        		                     -9,821,000           
          adjustments to reconcile net income to net cash from operating activities:
        		                                
          gain on disposal of fixed assets
        		                                
          purchase of investments
        		                                
          proceeds from sale of assets
        		                                
          proceeds from sale of common stock, net of issuance costs
        		                                
          purchases of property and equipment included in other non-current liabilities
        		                         -178,000 -307,000      
          191,152 shares of common stock issued in connection with the acquisition of umandiagnostics ab
        		                                
          fair value of common stock warrants exercised and reclassified as shares of common stock
        		                                
          acquisition of umandiagnostics ab, net of cash acquired
        		                                
          net decrease in cash and cash equivalents
        		                        -12,744,000        
          inventory valuation adjustment amortization
        		                                
          change in fair value of preferred stock warrants
        		                                
          deposits
        		                                
          proceeds from sale of preferred stock, net of issuance costs
        		                                
          proceeds from exercise of stock warrants
        		                                
          proceeds from the issuance of notes payable and warrants, net of issuance costs
        		                                
          accretion of redeemable convertible preferred stock to redemption value
        		                                
          warrants issued to lenders
        		                                
          net proceeds from at-the-market offering
        		                          0      
          net proceeds from underwritten public offering
        		                                
          191,152 shares of common stock issued in connection with the acquisition of uman
        		                                
          net cash provided (used in) by financing activities
        		                            831,000    
          accrued compensation and benefits, other accrued expenses and other liabilities
        		                                
          proceeds from the issuance of long term debt and warrants, net of issuance costs
        		                                
          payments on long term debt
        		                                
          net cash (used in) provided by financing activities
        		                                
          cash and cash equivalents at beginning of period
        		                              0 79,682,000 
          cash and cash equivalents at end of period
        		                              -4,757,000 65,231,000